MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Pleural

Malignant pleural mesothelioma; mesothelioma of the lining of the lungs, or pleura.

Familial risk of pleural mesothelioma increased drastically in certain occupations: A nationwide prospective cohort study.

European Journal of Cancer 2018 September 6 [Link] Kharazmi E, Chen T, Fallah M, Sundquist K, Sundquist J, Albin M, Weiderpass E, Hemminki K Abstract OBJECTIVE: We aimed to explore the effect of occupation on familial risk of pleural mesothelioma in a nationwide cohort study design. METHOD: The nationwide Swedish Family-Cancer Database includes all Swedes […]

Comments Off on Familial risk of pleural mesothelioma increased drastically in certain occupations: A nationwide prospective cohort study.

Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).

Quality of Life Research 2018 September 5 [Link] Williams LA, Whisenant MS, Mendoza TR, Haq S, Keating KN, Cuffel B, Cleeland CS Abstract PURPOSE: Malignant pleural mesothelioma (MPM) is an aggressive cancer of the lung pleura. The MD Anderson Symptom Inventory (MDASI) is a patient-reported outcome (PRO) measure of symptom burden, the combined impact of […]

Comments Off on Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).

Zoledronic acid in the management of mesothelioma – a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial.

Trials 2018 August 29 [Link] de Fonseka D, Morley A, Stadon L, Keenan E, Walker S, Smith S, Harvey JE, Cox RA, Dangoor A, Comins C, Rogers C, Edey A, Addeo A, Maskell NA Abstract BACKGROUND: Nitrogen containing bisphosphonates such as zoledronic acid (ZA) are known to contain certain anti-cancer properties. These have been investigated […]

Comments Off on Zoledronic acid in the management of mesothelioma – a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial.

Anesthetic Management of Pleurectomy/Decortication Under Differential Lung Ventilation.

The Kurume Medical Journal 2018 August 30 [Link] Kimura H, Hiraki T, Arata S, Ushijima K Abstract A 64-year-old male (a building demolition worker) was diagnosed with malignant left-sided pleural mesothelioma, and left-sided pleurectomy/decortication was scheduled. Differential lung ventilation (DLV) was performed during the removal of the visceral pleura by connecting the affected lung to […]

Comments Off on Anesthetic Management of Pleurectomy/Decortication Under Differential Lung Ventilation.

Ancillary studies in pleural, pericardial, and peritoneal effusion cytology.

Cancer Cytopathology 2018 August [Link] Sundling KE, Cibas ES Abstract Pleural, pericardial, and peritoneal effusion specimens present diagnostic challenges and clinical opportunities for cytology. For the patient, these specimens may be the first diagnosis of malignancy or the first sign of disease recurrence. This review aims to provide useful approaches with which to resolve key […]

Comments Off on Ancillary studies in pleural, pericardial, and peritoneal effusion cytology.

BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.

PloS One 2018 August 29 [Link] Rath EM, Cheng YY, Pinese M, Sarun KH, Hudson AL, Weir C, Wang YD, Håkansson AP, Howell VM, Liu GJ, Reid G, Knott RB, Duff Abstract Malignant pleural mesothelioma is an aggressive cancer with poor prognosis. Here we have investigated in vitro efficacy of BAMLET and BLAGLET complexes (anti-cancer […]

Comments Off on BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.

Early-stage Clinical Characterization of Malignant Pleural Mesothelioma.

In Vivo 2018 September-October [Link] Negi Y, Kuribayashi K, Funaguchi N, Doi H, Mikami K, Minami T, Takuwa T, Yokoi T, Hasegawa S, Ki Abstract BACKGROUND/AIM: A strategy for improving survival of malignant pleural mesothelioma (MPM) patients is earlier diagnosis paired with earlier stage implementation of therapeutic interventions. This study aimed to determine the clinical […]

Comments Off on Early-stage Clinical Characterization of Malignant Pleural Mesothelioma.

Current treatments and trials in malignant pleural mesothelioma.

The Clinical Respiratory Journal 2018 July 12 [Link] Bibby AC, Maskell NA Abstract OBJECTIVES: This article aims to review the evidence from recent clinical trials in mesothelioma, and to provide an overview of relevant clinical trials that are currently in progress. DATA SOURCE: Ovid MEDLINE, 1946 to present. STUDY SELECTION: Clinical trials of therapeutic interventions […]

Comments Off on Current treatments and trials in malignant pleural mesothelioma.

Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.

Pathology 2018 August 22 [Link] Forest F, Patoir A, Dal Col P, Sulaiman A, Camy F, Laville D, Bayle-Bleuez S, Fournel P, Habougit C Abstract For malignant pleural mesothelioma (MPM), histopathological subtype is one of the most important prognostic factors. Several immunohistochemical stains whose expressions have possible therapeutic implications have been identified in MPM such […]

Comments Off on Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.

5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin

Multidisciplinary Respiratory Medicine 2018 August 2 [Link] Bosio M, Salvaterra E, Datturi F, Morbini P, Zorzetto M, Inghilleri S, Tomaselli S, Mangiarotti P, Meloni F, Cerveri I, Stella GM Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis, mainly associated with work or environmental exposure to asbestos. MPM’s molecular profile is […]

Comments Off on 5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin